https://www.ophthalmologytimes.com/view/a-short-term-sustained-release-insert-can-offset-treatment-burden 2025-06-17 0.50 https://www.ophthalmologytimes.com/view/diabetic-retinopathy-screenings-offered-this-week-through-ainnova-partnerships 2025-06-18 0.50 https://www.ophthalmologytimes.com/view/pattern-laser-indirect-ophthalmoscope-in-first-10-patients 2025-06-16 0.50 https://www.ophthalmologytimes.com/view/sustained-anti-vegf-therapy-pros-and-cons-of-the-pds-for-treating-retinal-disease 2025-06-16 0.50 https://www.ophthalmologytimes.com/view/optogenetics-for-retinal-disease 2025-07-22 0.50 https://www.ophthalmologytimes.com/view/eyecare-partners-releases-quality-and-outcomes-report-highlights-optometric-successes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-june-9-to-june-13 2025-06-13 0.50 https://www.ophthalmologytimes.com/view/early-diabetic-retinopathy-detection-may-be-found-in-biomarker-changes 2025-07-22 0.50 https://www.ophthalmologytimes.com/view/hiv-drug-lamivudine-holds-potential-for-patients-with-dme-researchers-find 2025-06-11 0.50 https://www.ophthalmologytimes.com/view/amd-ai-and-the-future-of-eye-imaging-inside-the-2025-international-spectralis-symposium 2025-06-10 0.50 https://www.ophthalmologytimes.com/view/zeiss-fundus-imaging-device-receives-nmpa-approval-in-china 2025-06-10 0.50 https://www.ophthalmologytimes.com/view/anonymous-40-million-gift-received-by-university-of-colorado-anschutz-medical-campus-ophthalmology-department 2025-06-09 0.50 https://www.ophthalmologytimes.com/view/nih-researchers-identify-how-brain-circuits-are-affected-by-retinal-cell-damage 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocugen-signs-term-sheet-for-korean-licensing-of-ocu400-gene-therapy 2025-06-10 0.50 https://www.ophthalmologytimes.com/view/brazil-s-anvisa-grants-marketing-authorization-to-lucentis-biosimilar-fyb201-ranivisio-formycon-bioeq-ag- 2025-06-12 0.50 https://www.ophthalmologytimes.com/view/retina-roundup-june-2-to-june-6 2025-06-06 0.50 https://www.ophthalmologytimes.com/view/rebranded-veongen-therapeutics-announces-rare-pediatric-disease-designation-for-vg801 2025-06-05 0.50 https://www.ophthalmologytimes.com/view/3d-choroidal-vessel-imaging-offers-new-insights-into-retinal-diseases 2025-06-05 0.50 https://www.ophthalmologytimes.com/view/silicon-free-plunger-for-ophthalmic-drug-delivery 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/kiora-pharmaceuticals-and-senju-pharmaceutical-partner-on-kio-301-for-retinal-disease-treatment-in-asia 2025-06-05 0.50 https://www.ophthalmologytimes.com/view/eylea-8mg-in-focus-key-learnings-from-the-pivotal-trials 2025-06-03 0.50 https://www.ophthalmologytimes.com/view/study-highlights-retinal-vulnerability-in-patients-with-bipolar-and-depressive-disorders 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/retina-world-congress-global-innovations-transforming-treatment-strategies 2025-06-02 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-closes-enrollment-in-phase-3-sol-r-clinical-trial-for-wet-amd 2025-06-02 0.50 https://www.ophthalmologytimes.com/view/rapid-improvements-in-dme-with-next-generation-anti-vegf-therapies-case-highlights 2025-06-10 0.50 https://www.ophthalmologytimes.com/view/new-suprachoroidal-injection-reduces-diabetic-retinopathy-complications 2025-06-02 0.50 https://www.ophthalmologytimes.com/view/improved-retinal-drying-and-treatment-durability-in-namd-qith-aflibercept-8mg 2025-06-10 0.50 https://www.ophthalmologytimes.com/view/bilateral-central-retinal-artery-occlusion-following-paclitaxel-therapy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/geographic-atrophy-treatment-high-attrition-rates-challenge-long-term-patient-compliance 2025-07-22 0.50 https://www.ophthalmologytimes.com/view/faricimab-improves-vision-for-minority-patients-with-diabetic-macular-edema 2025-05-30 0.50 https://www.ophthalmologytimes.com/view/post-hoc-analysis-of-gather1-and-gather2-data 2025-05-30 0.50 https://www.ophthalmologytimes.com/view/innovative-uveitis-therapies-targeting-inflammation-macular-edema 2025-05-29 0.50 https://www.ophthalmologytimes.com/view/early-uveitis-detection-and-intervention-is-key-to-vision-preservation-systemic-health 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/strategic-investment-between-topcon-and-pangaea 2025-05-29 0.50 https://www.ophthalmologytimes.com/view/david-tanzer-md-cmo-of-lexitas-reflects-on-retina-world-congress 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/nih-scientists-develop-new-surgical-technique-for-grafting-tissue-in-the-retina 2025-05-28 0.50 https://www.ophthalmologytimes.com/view/sophie-deng-named-2025-2026-arvo-president 2025-05-27 0.50 https://www.ophthalmologytimes.com/view/metabolomic-profiling-of-vitreous-humor-reveals-stage-specific-biomarkers-in-diabetic-retinopathy 2025-05-27 0.50 https://www.ophthalmologytimes.com/view/ocugen-s-ocu410st-receives-rare-pediatric-disease-designation-for-the-treatment-of-abca4-associated-retinopathies 2025-05-27 0.50 https://www.ophthalmologytimes.com/view/eyepoint-announces-enrollment-of-lugano-phase-3-trial 2025-05-27 0.50 https://www.ophthalmologytimes.com/view/nasa-astronauts-to-keynote-2025-internatioal-spectralis-symposium-in-heidelberg 2025-05-28 0.50 https://www.ophthalmologytimes.com/view/diffuse-trickling-faf-pattern-linked-to-greater-ellipsoidal-zone-loss-in-ga 2025-05-22 0.50 https://www.ophthalmologytimes.com/view/health-care-leader-coalition-launches-alliance-for-healthcare-from-the-eye-initiative 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/irora-phenotypes-identified-through-fundus-autofluorescence-imaging 2025-05-23 0.50 https://www.ophthalmologytimes.com/view/fda-grants-breakthrough-therapy-designation-for-tinlarebant 2025-05-22 0.50 https://www.ophthalmologytimes.com/view/early-intervention-helps-with-vision-protection-in-macular-degeneration 2025-05-23 0.50 https://www.ophthalmologytimes.com/view/researchers-develop-ai-system-that-clarifies-images-of-rpe-making-cells-visible 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/genentech-s-susvimo-receives-new-fda-indication-for-diabetic-retinopathy 2025-05-22 0.50 https://www.ophthalmologytimes.com/view/researchers-find-alzheimer-disease-detection-potential-in-blood-based-retinal-biomarkers 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/intalight-s-dream-oct-platform-receives-ce-mark 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ai-systems-demonstrate-promising-potential-for-dr-screening-study-finds 2025-05-19 0.50 https://www.ophthalmologytimes.com/view/lineage-to-announce-data-from-phase-1-2a-study-on-use-of-rg6501 2025-05-19 0.50 https://www.ophthalmologytimes.com/view/new-retinotomy-technique-reduces-retinal-surgery-complications-improves-recovery 2025-05-19 0.50 https://www.ophthalmologytimes.com/view/retinal-nonperfusion-reveals-advanced-diabetic-eye-risk 2025-05-20 0.50 https://www.ophthalmologytimes.com/view/therini-bio-raises-39-million-in-a-series-a-extension-financing 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/kriya-825-gene-therapy-data-announced 2025-05-19 0.50 https://www.ophthalmologytimes.com/view/positive-interim-phase-2-results-for-mgb 2025-05-16 0.50 https://www.ophthalmologytimes.com/view/rhone-x-trial-evaluates-extended-dosing-for-dme-patients 2025-05-16 0.50 https://www.ophthalmologytimes.com/view/sylentis-announces-topline-results-of-syl1801phase-2a-study 2025-05-16 0.50 https://www.ophthalmologytimes.com/view/structure-function-link-between-ellipsoid-zone-integrity-features-and-visual-acuity-in-eyes-with-ga 2025-05-15 0.50 https://www.ophthalmologytimes.com/view/lumithera-announces-top-line-results-from-lightsite-iiib-extension-trial-assessing-the-valeda-light-delivery-system 2025-05-14 0.50 https://www.ophthalmologytimes.com/view/kapil-mishra-discusses-radiation-retinopathy-in-uveal-melanoma 2025-05-15 0.50 https://www.ophthalmologytimes.com/view/living-with-ga-how-patients-in-the-us-and-western-europe-cope 2025-05-13 0.50 https://www.ophthalmologytimes.com/view/role-of-ai-global-collaboration-in-ophthalmology-s-future 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/hypoglycemia-may-promote-a-breakdown-of-the-blood-retinal-barrier 2025-05-13 0.50 https://www.ophthalmologytimes.com/view/positive-preclinical-data-on-melanocortin-agonists-for-retinopathy 2025-05-13 0.50 https://www.ophthalmologytimes.com/view/new-research-raises-questions-about-the-current-clinical-approach-to-inherited-retinal-diseases 2025-05-13 0.50 https://www.ophthalmologytimes.com/view/aavantgarde-bio-presents-positive-data-for-retinitis-pigmentosa-and-stargardt-disease-therapies 2025-05-13 0.50 https://www.ophthalmologytimes.com/view/the-role-of-octa-in-detecting-retinal-microvascular-abnormalities-in-sle-patients 2025-05-12 0.50 https://www.ophthalmologytimes.com/view/status-of-baseline-central-subfield-ellipsoid-zone-predictive-of-future-visual-loss 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/patient-comfort-and-using-chlorhexidine-for-anti-sepsis 2025-05-12 0.50 https://www.ophthalmologytimes.com/view/boehringer-ingelheim-launches-two-phase-2-clinical-trials-for-its-geographic-atrophy-treatment-candidates 2025-05-09 0.50 https://www.ophthalmologytimes.com/view/q-a-katherine-talcott-md-on-exploring-a-potential-connection-between-autoimmune-diseases-and-amd 2025-05-10 0.50 https://www.ophthalmologytimes.com/view/rwc-2025-update-on-the-verona-trial-for-diabetic-macula-edema 2025-07-28 0.50 https://www.ophthalmologytimes.com/view/q-a-alan-j-franklin-md-phd-speaks-to-the-use-of-intraoperative-fluorescein-angiography 2025-05-10 0.50 https://www.ophthalmologytimes.com/view/rwc-2025-updates-on-the-helios-trial-for-diabetic-retinopathy 2025-05-10 0.50 https://www.ophthalmologytimes.com/view/optigo-bio-receives-people-s-choice-award-for-its-proprietary-drug-anchoring 2025-05-09 0.50 https://www.ophthalmologytimes.com/view/oral-zervimesine-reduced-ga-lesion-growth-in-phase-2-study-from-cognition-therapeutics 2025-05-08 0.50 https://www.ophthalmologytimes.com/view/assessment-of-ai-enabled-screening-for-rop-in-low-resource-settings 2025-05-07 0.50 https://www.ophthalmologytimes.com/view/innovent-biologics-completes-first-patient-dosing-in-its-phase-2-clinical-trial-assessing-efdamrofusp-alfa-in-patients-with-dme 2025-05-07 0.50 https://www.ophthalmologytimes.com/view/arvo-2025-carl-danzig-md-recaps-the-first-stage-of-a-phase-3-study-of-drop-based-dme-therapy-oculis-diamond-ocs-01-diabetic-macular-edema 2025-05-07 0.50 https://www.ophthalmologytimes.com/view/topcon-announces-launch-of-idhea 2025-05-07 0.50 https://www.ophthalmologytimes.com/view/galimedix-therapeutics-completes-single-ascending-dose-portion-of-phase-1-trial-assessing-gal-101 2025-05-07 0.50 https://www.ophthalmologytimes.com/view/innovent-biologics-announced-latest-data-on-ibi302 2025-05-07 0.50 https://www.ophthalmologytimes.com/view/repeated-anti-vegf-injections-do-not-cause-vascular-issue-in-patients-with-amd 2025-05-07 0.50 https://www.ophthalmologytimes.com/view/arvo-2025-early-intervention-is-crucial-for-patients-with-sickle-cell-retinopathy 2025-05-06 0.50 https://www.ophthalmologytimes.com/view/subretinal-drusenoid-deposits-marker-for-unrecognized-cardiac-disease 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/opgx-lca5-gene-therapy-phase-1-2-data-support-potential-to-restore-meaningful-vision 2025-05-06 0.50 https://www.ophthalmologytimes.com/view/ani-pharmaceuticals-announces-data-on-use-of-cortrophin-gel 2025-05-05 0.50 https://www.ophthalmologytimes.com/view/arvo-2025-christine-kay-md-shares-interim-results-from-the-prism-trial-population-extension-cohort 2025-05-05 0.50 https://www.ophthalmologytimes.com/view/arvo-2025-rishi-singh-md-discusses-real-world-clinical-outcomes-in-patients-with-dme 2025-05-05 0.50 https://www.ophthalmologytimes.com/view/j-j-gene-therapy-treatment-fails-primary-endpoints 2025-05-05 0.50 https://www.ophthalmologytimes.com/view/results-from-preclinical-study-kio-104-released 2025-05-05 0.50 https://www.ophthalmologytimes.com/view/first-patient-dosed-in-van-2401-phase-1-clinical-trial 2025-05-05 0.50 https://www.ophthalmologytimes.com/view/4d-molecular-therapeutics-receives-rmat-designation-for-4d-150-for-the-treatment-of-diabetic-macular-edema 2025-05-01 0.50 https://www.ophthalmologytimes.com/view/tavo-biotherapeutics-announces-two-new-senior-leaders 2025-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2025-editorial-board-members-set-to-present-data 2025-04-29 0.50 https://www.ophthalmologytimes.com/view/fda-grants-clearance-of-ocumet-beacon 2025-05-01 0.50 https://www.ophthalmologytimes.com/view/case-3-achieving-rapid-fluid-resolution-in-namd-with-faricimab 2025-05-01 0.50 https://www.ophthalmologytimes.com/view/case-2-treatment-naive-dme-with-gradual-visual-and-anatomical-gains-using-aflibercept-8-mg 2025-05-01 0.50 https://www.ophthalmologytimes.com/view/case-1-managing-suboptimal-response-in-bilateral-namd-transitioning-from-biosimilars-to-high-dose-aflibercept-for-durable-drying 2025-05-01 0.50 https://www.ophthalmologytimes.com/view/editorial-board-members-to-present-at-retina-world-congress-2025 2025-04-28 0.50 https://www.ophthalmologytimes.com/view/may-declared-as-ird-and-genetic-testing-month 2025-04-30 0.50 https://www.ophthalmologytimes.com/view/a-genetic-link-between-schizophrenia-and-retinal-thinning 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/regeneron-to-highlight-real-world-efficacy-of-aflibercept-8-mg-eylea-hd-in-wamd-dme-and-dr 2025-04-28 0.50 https://www.ophthalmologytimes.com/view/daniela-ferrara-appointed-by-topcon-healthcare-as-cmo 2025-04-28 0.50 https://www.ophthalmologytimes.com/view/wave-of-the-future-partnership-between-eye-care-and-psychology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/central-choroidal-thickness-important-biomarker-for-assessing-response-to-aflibercept-in-treatment-naive-dme 2025-04-25 0.50 https://www.ophthalmologytimes.com/view/when-the-world-went-virtual-how-ophthalmology-s-conferences-stayed-on-track 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/a-decade-of-uveitis-trends-in-diagnosis-and-disease-progression 2025-04-24 0.50 https://www.ophthalmologytimes.com/view/eye-care-industry-leaders-met-at-the-white-house-to-discuss-tariff-implications 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/prototype-oz-system-stimulates-thousands-of-m-cone-cells-on-the-threshold-of-new-ocular-experimentation 2025-04-24 0.50 https://www.ophthalmologytimes.com/view/researchers-develop-virus-like-particle-to-enhance-editing-proteins-causing-inherited-eye-diseases 2025-04-23 0.50 https://www.ophthalmologytimes.com/view/the-first-retina-sunday-program-debuts-at-this-year-s-ascrs-and-asoa-annual-meetings 2025-04-23 0.50 https://www.ophthalmologytimes.com/view/beth-marsh-appointed-as-new-neurotech-chief-commercial-officer 2025-04-21 0.50 https://www.ophthalmologytimes.com/view/using-retinal-images-to-classify-metabolic-syndrome 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/regeneron-announces-fda-issues-crl-for-aflibercept-8-mg-eylea-hd-sbla 2025-04-21 0.50 https://www.ophthalmologytimes.com/view/ai-powered-biomarker-segmentation-enhances-precision-in-monitoring-namd 2025-04-18 0.50 https://www.ophthalmologytimes.com/view/racial-disparities-in-visual-outcomes-of-ranibizumab-treated-dme 2025-04-18 0.50 https://www.ophthalmologytimes.com/view/rwc-2025-companies-to-share-data-at-meeting-in-fort-lauderdale 2025-05-01 0.50 https://www.ophthalmologytimes.com/view/fda-accepts-regeneron-s-sbla-for-eylea-hd-as-priority-review 2025-04-18 0.50 https://www.ophthalmologytimes.com/view/fda-grants-regenerative-medicine-advanced-therapy-designation-to-atsn-201-for-x-linked-retinoschisis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-announces-leadership-promotions 2025-04-14 0.50 https://www.ophthalmologytimes.com/view/biocon-regeneron-settle-to-launch-aflibercept-biosimilar-yesafili-in-the-us 2025-04-15 0.50 https://www.ophthalmologytimes.com/view/effect-of-social-media-on-follow-up-in-congenital-ectopic-lentis 2025-04-18 0.50 https://www.ophthalmologytimes.com/view/eyestem-reports-promising-phase-1-trial-results-in-patients-with-geographic-atrophy 2025-04-18 0.50 https://www.ophthalmologytimes.com/view/new-guidelines-boost-choriocapillaris-imaging-in-amd-with-ss-octa 2025-04-11 0.50 https://www.ophthalmologytimes.com/view/jeffrey-nau-named-ceo-of-aviceda-therapeutics 2025-04-11 0.50 https://www.ophthalmologytimes.com/view/first-patient-dosed-in-vantage-biosciences-phase-2-study-of-vx-01-for-non-proliferative-diabetic-retinopathy 2025-04-14 0.50 https://www.ophthalmologytimes.com/view/a-turning-point-in-retinal-neovascular-diseases 2025-04-11 0.50 https://www.ophthalmologytimes.com/view/ai-label-system-enhances-training-accuracy-in-retinal-disease-diagnosis 2025-04-11 0.50 https://www.ophthalmologytimes.com/view/enhanced-oct-ga-segmentation-achieved-with-new-multistage-model 2025-04-11 0.50 https://www.ophthalmologytimes.com/view/pykus-therapeutics-announces-completion-of-enrollment-in-pyk-2101-clinical-trial 2025-04-10 0.50 https://www.ophthalmologytimes.com/view/link-between-fasting-c-peptide-and-diabetic-retinopathy-in-people-with-type-2-diabetes-mellitus 2025-04-09 0.50 https://www.ophthalmologytimes.com/view/novelty-nobility-joins-jlabs-korea 2025-04-09 0.50 https://www.ophthalmologytimes.com/view/bayer-files-ema-application-for-aflibercept-8mg-in-third-indication-retinal-vein-occlusion 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-accepts-outlook-therapeutics-updated-biologics-license-application-for-ons-5010-to-treat-wet-amd 2025-04-09 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-issues-1-month-pediatric-gene-therapy-results 2025-04-08 0.50 https://www.ophthalmologytimes.com/view/summaries-generated-by-large-language-models-enhance-communication-across-different-disciplines-in-ophthalmology- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/doctors-warn-tiktok-instagram-reels-may-be-damaging-eyes-long-term 2025-04-07 0.50 https://www.ophthalmologytimes.com/view/uveitis-in-pediatric-patients-with-atopic-dermatitis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/a-case-of-retinal-detachment-in-tertiary-syphilis 2025-04-04 0.50 https://www.ophthalmologytimes.com/view/the-congress-on-controversies-in-ophthalmology-cophy-highlights-debates-in-surgical-medical-retina 2025-04-04 0.50 https://www.ophthalmologytimes.com/view/a-real-world-analysis-of-an-artificial-intelligence-system-for-improved-detection-of-diabetic-retinopathy- 2025-04-04 0.50 https://www.ophthalmologytimes.com/view/fda-issues-complete-response-letter-to-aldeyra-therapeutics-for-resubmitted-new-drug-application-of-reproxalap 2025-04-08 0.50 https://www.ophthalmologytimes.com/view/a-novel-radiosurgical-platform-to-treat-a-case-of-uveal-melanoma 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocular-effects-of-methylphenidate-in-children-and-adolescents-with-adhd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocular-involvement-in-multiple-myeloma 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-declares-april-as-women-s-eye-health-and-safety-month 2025-04-01 0.50 https://www.ophthalmologytimes.com/view/international-study-illuminates-economic-burden-of-late-stage-age-related-macular-degeneration 2025-03-31 0.50 https://www.ophthalmologytimes.com/view/study-no-significant-long-term-benefits-found-in-cocoa-extract-for-amd 2025-03-31 0.50 https://www.ophthalmologytimes.com/view/opthea-discontinues-coast-and-shore-trials-in-wet-amd 2025-03-31 0.50 https://www.ophthalmologytimes.com/view/association-between-ophthalmic-structures-and-fibromyalgia-syndrome 2025-03-27 0.50 https://www.ophthalmologytimes.com/view/internal-limiting-membrane-staining-dye-ilm-blue-from-dorc-zeiss-receives-nmpa-approval-in-china 2025-03-27 0.50 https://www.ophthalmologytimes.com/view/erg-provides-insight-into-duration-of-the-intravitreal-dexamethasone-implant 2025-03-25 0.50 https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-publishes-clinical-data-on-vision-restoration-in-retinitis-pigmentosa 2025-03-26 0.50 https://www.ophthalmologytimes.com/view/character-biosciences-secures-93-million-series-b-financing-round 2025-03-25 0.50 https://www.ophthalmologytimes.com/view/moorfields-eye-hospital-insight-research-hub-will-collaborate-with-artificial-intelligence-development-company-insitro 2025-03-25 0.50 https://www.ophthalmologytimes.com/view/zeiss-visulas-combi-availability-expands-to-canada 2025-03-24 0.50 https://www.ophthalmologytimes.com/view/opthea-phase-3-clinical-trial-coast-in-patients-with-wet-age-related-macular-degeneration-fails-to-meet-primary-endpoint 2025-04-17 0.50 https://www.ophthalmologytimes.com/view/unity-biotechnology-releases-topline-results-from-phase-2b-aspire-trial-of-ubx1325-in-patients-with-diabetic-macular-edema 2025-03-25 0.50 https://www.ophthalmologytimes.com/view/importance-of-evaluating-cerebrospinal-fluid-at-vitreoretinal-lymphoma-diagnosis 2025-03-21 0.50 https://www.ophthalmologytimes.com/view/how-covid-19-shifted-ophthalmologist-patient-communication 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocugen-to-move-forward-with-dosing-of-second-cohort-of-phase-1-clinical-trial-of-ocu200 2025-03-21 0.50 https://www.ophthalmologytimes.com/view/the-recent-agreement-with-cipla-adds-to-the-list-of-partnerships-formosa-has-formed-for-app13007- 2025-03-26 0.50 https://www.ophthalmologytimes.com/view/investigators-highlight-the-risk-of-misdiagnosing-geographic-atrophy 2025-08-19 0.50 https://www.ophthalmologytimes.com/view/aflibercept-treat-and-extend-regimen-for-neovascular-amd-5-year-outcomes 2025-03-19 0.50 https://www.ophthalmologytimes.com/view/the-future-of-retina-new-targets-and-more-durable-solutions 2025-03-18 0.50 https://www.ophthalmologytimes.com/view/preclinical-study-of-kio-104-in-a-proliferative-vitreoretinopathy-model-accepted-for-poster-presentation-at-arvo-2025 2025-03-17 0.50 https://www.ophthalmologytimes.com/view/arvo-announces-recipients-of-the-2025-arvo-foundation-early-career-clinician-scientist-awards 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/allovir-inc-stockholders-vote-to-merge-with-kalaris-therapeutics-inc- 2025-03-17 0.50 https://www.ophthalmologytimes.com/view/bilateral-retinal-detachments-in-a-young-patient 2025-03-15 0.50 https://www.ophthalmologytimes.com/view/arvo-announces-swathi-kaliki-md-as-recipient-of-2025-ludwig-von-sallmann-clinician-scientist-award 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/first-patient-dosed-in-phase-1-2-astra-study-for-stargardt-disease-therapy-sb-007-splicebio- 2025-03-15 0.50 https://www.ophthalmologytimes.com/view/the-whys-and-wherefores-of-ophthalmic-electrophysiology-in-inflammatory-retinal-and-optic-nerve-disorders 2025-03-14 0.50 https://www.ophthalmologytimes.com/view/stealth-biotherapeutics-reached-50-percent-of-enrollment-target-in-phase-3-renew-study 2025-03-14 0.50 https://www.ophthalmologytimes.com/view/kodiak-sciences-completes-enrollment-in-phase-3-glow2-trial-of-tarcocimab-tedromer-in-patients-with-diabetic-retinopathy 2025-03-13 0.50 https://www.ophthalmologytimes.com/view/unity-biotechnology-inc-appoints-yehia-hashad-md-to-the-board-of-directors-and-science-committee 2025-03-11 0.50 https://www.ophthalmologytimes.com/view/renal-dysfunction-may-affect-intravitreal-conbercept-effectiveness-in-diabetic-macular-edema-treatment 2025-03-11 0.50 https://www.ophthalmologytimes.com/view/4dmt-enrolls-first-patient-in-phase-3-4front-1-evaluating-4d-150-for-the-treatment-of-wet-amd 2025-03-11 0.50 https://www.ophthalmologytimes.com/view/heidelberg-engineering-announces-two-day-international-spectralis-symposium 2025-03-10 0.50 https://www.ophthalmologytimes.com/view/choroidal-vascularity-index-findings-associated-with-mild-covid-19-pneumonia 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/pds-implant-matches-monthly-injections-in-efficacy-in-dme-treatment 2025-03-10 0.50 https://www.ophthalmologytimes.com/view/optos-reference-database-includes-highest-number-of-patients-of-any-cleared-us-database 2025-03-07 0.50 https://www.ophthalmologytimes.com/view/data-from-phase-1-2a-clinical-trial-evaluating-rpesc-rpe-4w-presented-at-77th-annual-wills-eye-conference 2025-03-07 0.50 https://www.ophthalmologytimes.com/view/per-launches-retina-resource-a-comprehensive-anti-vegf-education-and-information-tool 2025-03-07 0.50 https://www.ophthalmologytimes.com/view/fda-approves-revakinagene-taroretcel-lwey-encelto-for-macular-telangiectasia-type-2 2025-03-06 0.50 https://www.ophthalmologytimes.com/view/avirmax-biopharma-prepares-for-ind-enabling-study-of-abi-201 2025-03-04 0.50 https://www.ophthalmologytimes.com/view/ema-provides-positive-atmp-opinion-for-gene-therapy-products-ocu410-and-ocu410st 2025-03-04 0.50 https://www.ophthalmologytimes.com/view/data-from-phase-2b-of-opthea-limited-wet-amd-trial-published 2025-03-04 0.50 https://www.ophthalmologytimes.com/view/adverum-biotechnologies-initiates-phase-3-artemis-trial-evaluating-ixoberogene-soroparvovec-ixo-vec-in-patients-with-wet-amd 2025-03-04 0.50 https://www.ophthalmologytimes.com/view/pykus-therapeutics-secures-a-new-patent-retinal-sealant-pyk-2101 2025-03-04 0.50 https://www.ophthalmologytimes.com/view/companies-to-present-at-tc-cowen-45th-annual-health-care-conference 2025-03-04 0.50 https://www.ophthalmologytimes.com/view/the-retinal-thickness-and-choroidal-vascularity-index-in-smokers 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/outlook-therapeutics-resubmits-bla-for-ons-5010-for-treatment-of-wet-amd 2025-02-28 0.50 https://www.ophthalmologytimes.com/view/cdr-life-completes-fifth-milestone-and-is-recruiting-patients-for-phase-2-study-of-bi-771716 2025-02-28 0.50 https://www.ophthalmologytimes.com/view/cognition-therapeutics-announces-manuscript-publication-on-oral-drug-candidate-zervimesine-ct1812-for-treatment-of-dry-amd 2025-02-28 0.50 https://www.ophthalmologytimes.com/view/diagnos-inc-to-fda-pre-market-authorization-for-cara-system 2025-03-03 0.50 https://www.ophthalmologytimes.com/view/study-demonstrates-visual-acuity-improvements-following-gene-therapy-for-aipl1-associated-inherited-retinal-dystrophies 2025-02-27 0.50 https://www.ophthalmologytimes.com/view/alkeus-pharmaceuticals-establishes-new-scientific-advisory-board 2025-02-27 0.50 https://www.ophthalmologytimes.com/view/uk-mhra-issues-approval-for-aflibercept-biosimilar-fyb203-ahzantive-from-formycon 2025-02-27 0.50 https://www.ophthalmologytimes.com/view/fda-grants-rmat-designation-to-rpesc-rpe-4w-transplantation-for-amd 2025-02-27 0.50 https://www.ophthalmologytimes.com/view/retinal-detachment-risk-after-b1kpro 2025-02-27 0.50 https://www.ophthalmologytimes.com/view/arctic-vision-files-new-drug-application-in-china-for-candidate-to-treat-uveitic-macular-edema 2025-02-25 0.50 https://www.ophthalmologytimes.com/view/researchers-collaborate-on-eye-surgery-robot-at-university-of-utah 2025-02-25 0.50 https://www.ophthalmologytimes.com/view/retinalgenix-technologies-starts-imaging-patients-with-prototype-high-resolution-retinal-imaging-device 2025-02-24 0.50 https://www.ophthalmologytimes.com/view/national-eye-institute-awards-grant-to-support-ai-research-for-the-diagnosis-and-treatment-of-uveitis 2025-02-24 0.50 https://www.ophthalmologytimes.com/view/retinopathy-of-prematurity-rop-awareness-week-begins-february-24-2025 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/heart-eye-announces-ai-driven-retinal-imaging-system-to-detect-biomarkers-of-cardiovascular-health-risks 2025-02-24 0.50 https://www.ophthalmologytimes.com/view/sexual-harassment-remains-high-in-ophthalmology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/alvotech-and-teva-pharmaceuticals-announce-fda-accepts-biologics-license-application-for-avt06 2025-02-19 0.50 https://www.ophthalmologytimes.com/view/impact-of-durable-therapies-on-patients-and-clinics-and-monitoring-strategies 2025-02-21 0.50 https://www.ophthalmologytimes.com/view/hyperacute-outer-retinal-dysfunction-an-underrecognized-pediatric-disorder- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/opthea-limited-completes-week-52-patient-visits-in-the-coast-trial 2025-02-19 0.50 https://www.ophthalmologytimes.com/view/pulsesight-therapeutics-sas-receives-funds-to-support-clinical-trials-of-pst-611 2025-02-19 0.50 https://www.ophthalmologytimes.com/view/managing-retinal-detachment-in-morning-glory-syndrome 2025-02-18 0.50 https://www.ophthalmologytimes.com/view/optos-ushers-in-new-generation-of-imaging-with-monacopro-ultra-widefield-and-oct 2025-02-19 0.50 https://www.ophthalmologytimes.com/view/ocugen-inc-completes-dosing-in-phase-2-portion-of-armada-clinical-trial-for-ocu410 2025-02-18 0.50 https://www.ophthalmologytimes.com/view/the-pearls-and-pitfalls-of-ai-for-managing-geographic-atrophy 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/nominations-open-for-2-awards-presented-by-prevent-blindness 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/transforming-preinjection-protocols 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/snowmass-retina-eye-2025-ronald-frenkel-md-previews-the-unique-agenda-with-a-fusion-of-retina-cataract-and-glaucoma 2025-02-17 0.50 https://www.ophthalmologytimes.com/view/waiting-on-a-treatment-how-the-history-of-mactel-is-leading-us-into-the-future 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/companies-results-of-the-combination-of-topcon-s-retinal-camera-and-aeye-diagnostic-screening 2025-02-24 0.50 https://www.ophthalmologytimes.com/view/cvi-definition-a-work-in-progress 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/aurion-biotech-appoint-donald-munoz-as-chief-financial-officer 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/where-might-ai-be-heading- 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/the-power-of-home-monitoring 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/strategies-for-loading-dose-sse-for-treatment-naive-and-switch-patients 2025-02-14 0.50 https://www.ophthalmologytimes.com/view/perspectives-on-the-usefulness-of-real-world-data 2025-02-14 0.50 https://www.ophthalmologytimes.com/view/healthy-lifestyles-translate-to-lower-risk-of-retinal-disease 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/opthea-to-present-data-from-phase-2b-trial-of-sozinibercept-at-the-macula-society-48th-annual-meeting 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/ema-launches-procedure-for-manufacturers-working-with-high-risk-medical-devices 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-approves-amended-label-for-izervay-for-geographic-atrophy 2025-02-13 0.50 https://www.ophthalmologytimes.com/view/study-indicates-age-and-gender-are-factors-in-ocular-gene-therapy-outcomes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/a-new-technique-to-estimate-melanocytic-choroidal-tumor-thicknesses-without-b-scan-ultrasonography 2025-02-11 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-presents-new-data-from-cls-ax-odyssey-phase-2b-trial 2025-02-11 0.50 https://www.ophthalmologytimes.com/view/oct-biomarkers-predictive-of-vision-changes-in-namd 2025-02-11 0.50 https://www.ophthalmologytimes.com/view/study-finds-covid-19-led-to-significant-decline-in-common-eye-surgeries 2025-02-10 0.50 https://www.ophthalmologytimes.com/view/axovia-therapeutics-receives-grant-from-a-race-against-blindness-to-support-upcoming-clinical-trial 2025-02-10 0.50 https://www.ophthalmologytimes.com/view/bausch-lomb-provides-update-on-potential-sale 2025-02-10 0.50 https://www.ophthalmologytimes.com/view/4dmt-announces-positive-52-week-data-from-phase-2b-cohort-of-prism-wet-amd-study 2025-02-10 0.50 https://www.ophthalmologytimes.com/view/regeneron-reveals-positive-results-from-multiple-trials-evaluating-eylea-hd-aflibercept-injection-8-mg 2025-02-10 0.50 https://www.ophthalmologytimes.com/view/expert-insights-ramiro-ribeiro-md-phd-discusses-next-steps-in-eyp-1901-research 2025-02-07 0.50 https://www.ophthalmologytimes.com/view/safety-profile-of-new-therapies 2025-02-07 0.50 https://www.ophthalmologytimes.com/view/outcomes-with-raricimab-and-choosing-between-the-new-therapies 2025-02-07 0.50 https://www.ophthalmologytimes.com/view/italian-study-illuminates-positive-outcomes-and-common-complications-of-sing-imt-implantation 2025-02-07 0.50 https://www.ophthalmologytimes.com/view/refractory-namd-responds-well-to-faricimab 2025-02-04 0.50 https://www.ophthalmologytimes.com/view/tyrosine-kinase-inhibitors-to-prolong-efficacy-of-anti-vegf-therapies 2025-04-14 0.50 https://www.ophthalmologytimes.com/view/4dmt-to-host-webcast-on-interim-52-week-data-from-phase-2b-of-its-prism-clinical-trial 2025-02-03 0.50 https://www.ophthalmologytimes.com/view/expert-insights-ashkan-abbey-md-discusses-1-year-results-of-davio-2-trial 2025-02-05 0.50 https://www.ophthalmologytimes.com/view/study-investigates-neurological-impact-of-diabetic-vitreous-hemorrhage 2025-02-03 0.50 https://www.ophthalmologytimes.com/view/fda-approves-continuous-delivery-ranibizumab-injection-susvimo-for-the-treatment-of-diabetic-macular-edema 2025-02-04 0.50 https://www.ophthalmologytimes.com/view/notal-vision-publishes-positive-results-from-pivotal-study-of-ai-algorithm-in-home-based-oct-system 2025-02-03 0.50 https://www.ophthalmologytimes.com/view/covid-19-and-the-effects-on-the-retinal-microvascular-structure 2025-02-03 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-again-names-february-as-amd-and-low-vision-awareness-month 2025-02-03 0.50 https://www.ophthalmologytimes.com/view/beacon-therapeutics-receives-regenerative-medicine-advanced-therapy-designation-for-laruparetigene-zovaparvovec-laru-zova- 2025-02-03 0.50 https://www.ophthalmologytimes.com/view/ophthalmic-complications-observed-in-patients-taking-semaglutide-and-tirzepatide 2025-02-03 0.50 https://www.ophthalmologytimes.com/view/novel-intravitreal-injections-faricimab-and-aflibercept-8mg-for-the-treatment-of-retinal-diseases 2025-01-31 0.50 https://www.ophthalmologytimes.com/view/faricimab-molecular-design-and-role-of-ang-2 2025-01-31 0.50 https://www.ophthalmologytimes.com/view/adverse-events-of-the-port-delivery-system-and-addressing-challenges-with-adoption 2025-01-31 0.50 https://www.ophthalmologytimes.com/view/patient-selection-for-aflibercept-8-mg 2025-01-31 0.50 https://www.ophthalmologytimes.com/view/successful-treatment-of-rpe65-mediated-inherited-retinal-dystrophy-with-voretigene-neparvovec 2025-02-04 0.50 https://www.ophthalmologytimes.com/view/seabelife-announces-preclinical-efficacy-results-for-sbl03-topical-ophthalmic-gel 2025-01-30 0.50 https://www.ophthalmologytimes.com/view/macustar-receives-additional-ema-support-for-amd-clinical-study 2025-01-30 0.50 https://www.ophthalmologytimes.com/view/technique-for-refilling-the-pds 2025-01-30 0.50 https://www.ophthalmologytimes.com/view/ai-optics-portable-sentinel-camera-gains-fda-510-k-clearance 2025-01-29 0.50 https://www.ophthalmologytimes.com/view/patient-experiences-key-clinical-trial-outcomes-of-the-port-delivery-system 2025-01-29 0.50 https://www.ophthalmologytimes.com/view/key-steps-in-the-surgical-implantation-of-the-port-delivery-system 2025-01-29 0.50 https://www.ophthalmologytimes.com/view/harrow-launches-harrow-cares-program-in-partnership-with-cencora 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/a-study-of-the-3-year-clinical-outcomes-in-geographic-atrophy 2025-01-28 0.50 https://www.ophthalmologytimes.com/view/apellis-pharmaceuticals-receives-approval-of-pegcetacoplan-syfovre-for-treatment-of-geographic-atrophy-in-australia 2025-01-28 0.50 https://www.ophthalmologytimes.com/view/viralgen-and-axovia-therapeutics-partner-to-manufacture-gene-therapy-for-bardet-biedl-syndrome 2025-01-28 0.50 https://www.ophthalmologytimes.com/view/tyrosine-kinase-inhibitor-an-alternative-treatment-for-non-small-cell-lung-cancer-metastasis-to-the-choroid 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/researchers-identify-triangle-sign-as-key-diagnostic-marker-in-ocular-pathologies 2025-01-23 0.50 https://www.ophthalmologytimes.com/view/10-year-data-shows-progressive-visual-decline-in-myopic-children-and-adults 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/effects-of-premature-birth-on-the-retina-of-adults 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/neureye-team-leads-ai-research-to-detect-dementia-through-retinal-imaging 2025-01-23 0.50 https://www.ophthalmologytimes.com/view/study-design-for-pulsar-and-photon-trials-for-aflibercept-8-mg 2025-01-23 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-s-asia-pacific-partner-arctic-vision-receives-approval-for-suprachoroidal-treatment-for-uveitic-macular-edema-in-australia-and-singapore 2025-01-23 0.50 https://www.ophthalmologytimes.com/view/patient-selection-for-pds 2025-01-23 0.50 https://www.ophthalmologytimes.com/view/fda-grants-fast-track-designation-to-n-acetylcysteine-amide-tablets-from-nacuity-pharmaceuticals 2025-01-23 0.50 https://www.ophthalmologytimes.com/view/helios-trial-promising-1-year-results-of-phase-i-study-for-treating-npdr 2025-01-24 0.50 https://www.ophthalmologytimes.com/view/eylea-s-unique-moa-what-is-the-rationale-for-the-higher-molar-dose- 2025-01-29 0.50 https://www.ophthalmologytimes.com/view/potential-effect-of-temperature-changes-on-anti-vegf-drugs 2025-01-22 0.50 https://www.ophthalmologytimes.com/view/pulsesight-therapeutics-submits-clinical-trial-authorization-for-phase-i-trial-of-pst-611 2025-01-17 0.50 https://www.ophthalmologytimes.com/view/outlook-therapeutics-completes-analysis-of-12-week-safety-and-efficacy-results-of-norse-eight 2025-01-17 0.50 https://www.ophthalmologytimes.com/view/macrophomina-phaseolina-an-emerging-ocular-infection-in-humans 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/significance-of-the-higher-molar-dose-of-aflibercept-8-mg 2025-01-23 0.50 https://www.ophthalmologytimes.com/view/considerations-for-surgical-implant-of-the-port-delivery-system-and-refill-process 2025-01-29 0.50 https://www.ophthalmologytimes.com/view/patient-selection-for-port-delivery-device 2025-01-29 0.50 https://www.ophthalmologytimes.com/view/overview-and-benefits-of-port-delivery-device-with-ranibizumab 2025-01-29 0.50 https://www.ophthalmologytimes.com/view/cost-effectiveness-of-ai-pediatric-eye-screening 2025-01-15 0.50 https://www.ophthalmologytimes.com/view/inflammasome-therapeutics-announces-positive-topline-3-month-data-of-k8-implant-in-patients-with-ga 2025-01-16 0.50 https://www.ophthalmologytimes.com/view/rhygaze-secures-series-a-financing-of-86-million-to-further-novel-gene-therapy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/navigating-the-surgical-learning-curve-for-effective-pds-implantation 2025-01-16 0.50 https://www.ophthalmologytimes.com/view/eyepoint-pharmaceuticals-provides-company-updates-2025-milestones-for-duravyu 2025-01-15 0.50 https://www.ophthalmologytimes.com/view/inflammx-therapeutics-enters-into-option-agreement-with-bausch-lomb 2025-01-15 0.50 https://www.ophthalmologytimes.com/view/positive-association-between-the-dietary-inflammatory-index-and-non-refractive-visual-impairment-in-us-ppatients 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ashvattha-therapeutics-secures-50m-in-financing-to-advance-clinical-trials 2025-01-13 0.50 https://www.ophthalmologytimes.com/view/samsara-vision-announces-positive-intermediate-term-visual-and-safety-outcomes-of-sing-imt-6-months-post-surgery 2025-01-13 0.50 https://www.ophthalmologytimes.com/view/formycon-partners-with-teva-klinge-biopharma-for-commercialization-of-aflibercept-biosimilar-fyb203-ahzantive- 2025-01-13 0.50 https://www.ophthalmologytimes.com/view/4dmt-releases-positive-topline-interim-data-from-part-1-of-the-spectra-clinical-trial 2025-01-13 0.50 https://www.ophthalmologytimes.com/view/bausch-lomb-acquires-whitecap-biosciences 2025-01-13 0.50 https://www.ophthalmologytimes.com/view/positive-2-year-safety-and-efficacy-update-for-phase-1-2-ocu400-for-the-treatment-of-rp 2025-01-13 0.50 https://www.ophthalmologytimes.com/view/city-therapeutics-and-bausch-lomb-collaborate-on-ga-treatment-candidate 2025-01-13 0.50 https://www.ophthalmologytimes.com/view/new-research-links-retinal-imaging-and-deep-learning-to-improved-schizophrenia-detection 2025-01-10 0.50 https://www.ophthalmologytimes.com/view/topline-results-from-phase-2b-clinical-trial-of-ubx1325-for-dme-expected-in-q1-2025 2025-01-10 0.50 https://www.ophthalmologytimes.com/view/a-connection-between-sleep-apnea-and-amd 2025-01-10 0.50 https://www.ophthalmologytimes.com/view/the-fda-accepts-revised-supplemental-new-drug-application-for-izervay 2025-01-10 0.50 https://www.ophthalmologytimes.com/view/assessing-new-therapies-for-retinal-diseases 2025-01-10 0.50 https://www.ophthalmologytimes.com/view/companies-appoint-new-leadership-across-the-industry 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aviceda-therapeutics-completes-207-5-million-series-c-financing-in-support-of-avd-104-for-geographic-atrophy-treatment 2025-01-09 0.50 https://www.ophthalmologytimes.com/view/adverse-effects-associated-with-pds-and-surgical-considerations 2025-01-09 0.50 https://www.ophthalmologytimes.com/view/fda-grants-rare-pediatric-disease-designation-for-retinitis-pigmentosa-gene-therapy-candidate-vg901-from-vigeneron 2025-01-09 0.50 https://www.ophthalmologytimes.com/view/regeneron-acquires-uk-biotech-company-oxular-broadening-retina-portfolio 2025-01-07 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-funding-and-shelved-projects-updates-you-may-have-missed 2025-01-07 0.50 https://www.ophthalmologytimes.com/view/oculis-releases-positive-topline-results-from-phase-2-acuity-trial-evaluating-osc-05-in-acute-optic-neuritis 2025-01-07 0.50 https://www.ophthalmologytimes.com/view/korea-institute-of-science-and-technology-kist-enters-technology-transfer-agreement-with-huons-biopharma 2025-01-06 0.50 https://www.ophthalmologytimes.com/view/oct-and-octa-findings-in-fibromyalgia 2025-01-06 0.50 https://www.ophthalmologytimes.com/view/topcon-healthcare-appoints-jacques-gilbert-to-chief-strategy-and-business-development-officer 2025-01-03 0.50 https://www.ophthalmologytimes.com/view/european-medicines-agency-will-assess-semaglutide-for-link-to-naion 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/treat-and-extend-strategy-with-aflibercept 2025-01-03 0.50 https://www.ophthalmologytimes.com/view/restore-study-unilateral-genetic-treatment-for-lhon-with-positive-bilateral-results 2025-01-02 0.50 https://www.ophthalmologytimes.com/view/ocugen-will-continue-second-phase-of-ocu410-armada-clinical-trial 2025-01-03 0.50 https://www.ophthalmologytimes.com/view/combination-microdrops-for-rop-screening-fewer-systemic-adverse-events-than-standard-mydriatrics 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/overview-of-port-delivery-system-with-ranibizumab 2025-01-02 0.50 https://www.ophthalmologytimes.com/view/need-for-sustained-delivery-of-anti-vegf-in-retinal-diseases 2025-01-02 0.50 https://www.ophthalmologytimes.com/view/galimedix-therapeutics-initiates-edream-phase-2-clinical-trial-in-dry-age-related-macular-degeneration 2025-01-02 0.50 https://www.ophthalmologytimes.com/view/overview-of-novel-treatments-for-retinal-vascular-diseases 2025-01-29 0.50 https://www.ophthalmologytimes.com/view/emerging-insights-into-ocular-immune-related-diseases-and-treatment-options 2024-12-19 0.50 https://www.ophthalmologytimes.com/view/ophthalmology-times-2024-wrap-up-a-year-of-innovation-and-insight 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/2024-in-the-rearview-top-stories-from-this-year-in-optometry 2024-12-19 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-inc-set-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2024-12-11 0.50 https://www.ophthalmologytimes.com/view/ophthalmic-safety-notice-potential-fungal-contamination-prompts-systane-ultra-pf-voluntary-recall 2024-12-27 0.50 https://www.ophthalmologytimes.com/view/wrapping-up-another-year-in-european-eye-care-2024-in-review 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-diabetes-does-not-significantly-impact-outcomes-of-epiretinal-membrane-surgery 2024-12-13 0.50 https://www.ophthalmologytimes.com/view/eyecare-wrapped-top-stories-from-modern-retina-in-2024 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/modern-retina-in-print-the-4-issues-of-2024 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/evolving-anti-vegf-treatment-workload-for-retinal-diseases-in-southwest-finland 2024-12-13 0.50 https://www.ophthalmologytimes.com/view/comparison-of-brolucizumab-and-aflibercept-for-treating-dme 2024-12-13 0.50 https://www.ophthalmologytimes.com/view/addressing-barriers-to-annual-diabetic-retinopathy-screening 2024-12-16 0.50 https://www.ophthalmologytimes.com/view/curacle-presents-results-of-phase-2a-clinical-trial-of-cu06-for-diabetic-macular-edema 2024-12-19 0.50 https://www.ophthalmologytimes.com/view/4dmt-announces-the-publication-of-preclinical-data-in-investigative-ophthalmology-visual-science 2024-12-19 0.50 https://www.ophthalmologytimes.com/view/advantages-of-the-molecular-structure-of-aflibercept 2025-01-03 0.50 https://www.ophthalmologytimes.com/view/evolution-of-anti-vegf-agents-and-unmet-needs-in-retinal-diseases 2025-01-03 0.50 https://www.ophthalmologytimes.com/view/research-to-prevent-blindness-board-of-trustees-releases-statement-advocating-for-the-protection-of-the-national-eye-institute 2024-12-19 0.50 https://www.ophthalmologytimes.com/view/ema-chmp-issues-positive-opinion-for-aflibercept-biosimilar-two-other-candidates-from-celltrion 2024-12-16 0.50 https://www.ophthalmologytimes.com/view/essilorluxottica-enters-agreement-for-the-acquisition-of-espansione-group 2024-12-16 0.50 https://www.ophthalmologytimes.com/view/eyedna-therapeutics-receives-fda-rare-pediatric-disease-designation-for-hora-pde6b-a-novel-gene-therapy-for-pde6b-retinitis-pigmentosa 2024-12-18 0.50 https://www.ophthalmologytimes.com/view/researchers-awarded-2-7-million-nih-grant-to-study-retinal-connections-in-rp 2024-12-16 0.50 https://www.ophthalmologytimes.com/view/regeneron-announces-aflibercept-8mg-injection-meets-primary-endpoint-in-phase-3-quasar-trial-in-patients-with-retinal-vein-occlusion 2024-12-18 0.50 https://www.ophthalmologytimes.com/view/atsena-therapeutics-completes-dosing-in-part-a-of-phase-i-ii-clinical-trial-evaluating-atsn-201-to-treat-x-linked-retinoschisis 2024-12-16 0.50 https://www.ophthalmologytimes.com/view/european-medicines-agency-approves-faricimab-vabysmo-6-0-mg-single-dose-prefilled-syringe 2024-12-16 0.50 https://www.ophthalmologytimes.com/view/the-human-impact-of-geographic-atrophy-survey-examines-experiences-and-perceptions-of-patients-living-with-ga 2024-12-16 0.50 https://www.ophthalmologytimes.com/view/amd-halt-programme-receives-eurostars-grant-for-continued-investigation-of-dry-amd-gene-therapy-platform 2024-12-13 0.50 https://www.ophthalmologytimes.com/view/umass-memorial-health-integrates-aeye-health-s-aeye-ds-into-its-emr-system 2024-12-11 0.50 https://www.ophthalmologytimes.com/view/tenpoint-therapeutics-and-visus-therapeutics-complete-merger-combining-ophthalmic-therapeutics-portfolios 2024-12-13 0.50 https://www.ophthalmologytimes.com/view/study-links-lower-socioeconomic-status-to-increased-risk-of-open-globe-injury-and-poorer-outcomes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ray-kaczmarek-named-chief-technology-and-manufacturing-officer-of-nanoscope-therapeutics 2024-12-11 0.50 https://www.ophthalmologytimes.com/view/aaron-nagial-md-phd-gives-interview-on-the-impact-of-retinal-gene-therapy-procedure-conducted-at-children-s-hospital-los-angeles 2024-12-20 0.50 https://www.ophthalmologytimes.com/view/foundation-fighting-blindness-invites-applications-for-career-development-program 2024-12-11 0.50 https://www.ophthalmologytimes.com/view/accumulated-dna-damage-in-the-retina-is-a-key-contributor-to-amd 2024-12-09 0.50 https://www.ophthalmologytimes.com/view/serum-inflammation-biomarkers-level-in-cystoid-and-diffuse-diabetic-macular-edema 2024-12-11 0.50 https://www.ophthalmologytimes.com/view/pilot-program-designed-to-screen-for-diabetic-retinopathy-in-costa-rica 2024-12-09 0.50 https://www.ophthalmologytimes.com/view/nona-biosciences-and-kodiak-sciences-partner-to-develop-novel-antibodies-for-ophthalmic-diseases 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/phase-2b-3-trial-of-izokibep-in-non-infectious-non-anterior-uveitis-does-not-meet-primary-endpoint 2024-12-11 0.50 https://www.ophthalmologytimes.com/view/exegenesis-bio-provides-an-update-on-exg102-and-exg202-for-wet-amd 2024-12-09 0.50 https://www.ophthalmologytimes.com/view/discrimination-in-ophthalmology-in-the-us 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/industry-updates-from-floretina-icoor-2024 2024-12-09 0.50 https://www.ophthalmologytimes.com/view/recyclable-ophthalmic-instrument-company-hasa-optix-receives-b-corporation-certification 2024-12-09 0.50 https://www.ophthalmologytimes.com/view/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa 2024-12-09 0.50 https://www.ophthalmologytimes.com/view/delveinsight-releases-report-of-in-depth-background-and-trends-of-the-diabetic-macular-edema 2024-12-06 0.50 https://www.ophthalmologytimes.com/view/retinopathy-associated-with-hair-dye 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-suggests-visual-system-affected-in-patients-with-mild-traumatic-brain-injury 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/nerve-cells-of-blind-mice-retain-their-visual-function 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-crvo-patients-face-higher-heart-attack-risk 2024-12-05 0.50 https://www.ophthalmologytimes.com/view/outlook-therapeutics-reveals-preliminary-topline-results-of-norse-eight 2024-12-06 0.50 https://www.ophthalmologytimes.com/view/samsung-bioepis-names-kyung-ah-kim-president-and-chief-executive-officer-of-the-company 2024-12-06 0.50 https://www.ophthalmologytimes.com/view/galimedix-therapeutics-initiates-phase-1-trial-of-oral-gal-101 2024-12-05 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-inc-to-share-6-month-efficacy-and-safety-data-on-opgx-lca5 2024-12-03 0.50 https://www.ophthalmologytimes.com/view/eyepoint-doses-first-patient-in-second-global-phase-3-lucia-clinical-trial-of-duravyu-for-the-treatment-of-wet-amd 2024-12-05 0.50 https://www.ophthalmologytimes.com/view/advanced-research-projects-agency-for-health-awards-research-grants-to-fast-track-whole-eye-transplants 2024-12-03 0.50 https://www.ophthalmologytimes.com/view/ace-therapeutics-to-launch-custom-in-vivo-ocular-modeling-services 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/more-than-300-patients-randomized-in-the-sol-1-phase-3-trial-for-otx-tki 2024-12-03 0.50 https://www.ophthalmologytimes.com/view/ocugen-ceo-to-present-at-the-noblecon20-conference 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/oral-presentation-discussing-sozinibercept-set-for-the-annual-floretina-congress 2024-11-27 0.50 https://www.ophthalmologytimes.com/view/december-2--8-2024-named-geographic-atrophy-ga-awareness-week-by-prevent-blindness 2024-11-27 0.50 https://www.ophthalmologytimes.com/view/preclinical-results-show-mrna-based-treatment-effective-against-scarring-from-pvr 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/relapse-in-ocular-tuberculosis-study-reveals-one-third-of-cases-resurface-after-treatment 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/the-buzz-on-biosimilars-news-in-november-2024 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/researchers-find-new-model-of-neuronal-circuit-provides-insight-on-eye-movement 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ai-models-offer-hope-for-personalized-amd-treatment-plans 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/what-you-missed-at-aao-2024-abbv-rgx-314-for-wet-amd 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/octa-reveals-retinal-vascular-damage-in-patients-diagnosed-with-renal-hypertension-offers-early-diagnostic-insights 2024-11-25 0.50 https://www.ophthalmologytimes.com/view/what-you-missed-at-aao-2024-gildeuretinol-acetate-alk-001- 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/usc-researchers-receive-6-million-cirm-grant-to-advance-novel-dry-amd-therapy 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/opthea-appoints-kathy-connell-gaicd-to-the-board-of-directors 2024-11-19 0.50 https://www.ophthalmologytimes.com/view/european-medicines-agency-ema-grants-orphan-medicinal-product-designation-for-ocu410st 2024-11-22 0.50 https://www.ophthalmologytimes.com/view/avant-technologies-and-ainnova-tech-partner-to-advance-retinal-camera-with-ai-driven-diagnostic-platform 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/aromatherapy-decreased-postoperative-patient-anxiety-and-pain-associated-with-oculoplastic-surgery 2024-11-19 0.50 https://www.ophthalmologytimes.com/view/first-patient-dosed-in-phase-i-iia-clinical-trial-of-abi-110 2024-11-22 0.50 https://www.ophthalmologytimes.com/view/flagship-dataset-released-to-better-understand-type-2-diabetes-development 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/sunil-gupta-md-joins-the-nanoscope-therapeutics-inc-s-board-of-directors 2024-11-19 0.50 https://www.ophthalmologytimes.com/view/nih-announces-elements-of-brain-based-visual-impairment-in-children 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/the-fda-extends-the-pdufa-for-the-biologics-license-application-of-nt-501 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/harrow-to-reduce-prices-and-partner-with-goodrx 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/adverum-biotechnologies-shares-positive-52-week-luna-and-4-year-optic-results 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/opthea-to-present-at-upcoming-events-to-highlight-work-on-wet-amd 2024-11-19 0.50 https://www.ophthalmologytimes.com/view/arctic-vision-signs-a-new-commercial-collaboration-agreement-with-santen-pharmaceutical-co-ltd-for-arvn001 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/ocugen-announces-positive-preliminary-data-from-ocu410-phase-1-clinical-trial-for-geographic-atrophy 2024-11-19 0.50 https://www.ophthalmologytimes.com/view/excellence-across-the-board-at-the-2024-euretina-congress 2024-11-20 0.50 https://www.ophthalmologytimes.com/view/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations-for-gildeuretinol-as-treatment-for-stargardt-disease 2024-11-19 0.50 https://www.ophthalmologytimes.com/view/the-chmp-issues-positive-opinion-for-the-marketing-authorization-of-fyb203 2024-11-18 0.50 https://www.ophthalmologytimes.com/view/us-fda-issues-complete-response-letter-crl-avacincaptad-pegol-intravitreal-solution-izervay- 2024-11-19 0.50 https://www.ophthalmologytimes.com/view/a-memia-anecdotal-evidence-in-the-era-of-memes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/nhs-introduces-oct-program-to-reduce-annual-hospital-visits-for-patients-with-diabetes 2024-11-18 0.50 https://www.ophthalmologytimes.com/view/allovir-inc-enters-definitive-merger-agreement-to-combine-with-kalaris-therapeutics 2024-11-18 0.50 https://www.ophthalmologytimes.com/view/the-european-commission-approves-biosimilar-referencing-aflibercept-by-samsung-bioepis 2024-11-18 0.50 https://www.ophthalmologytimes.com/view/new-treatment-options-provide-effective-management-of-geographic-atrophy 2024-11-14 0.50 https://www.ophthalmologytimes.com/view/ocular-nerve-regrowth-following-use-of-diabetes-drug 2024-11-14 0.50 https://www.ophthalmologytimes.com/view/merger-of-akari-therapeutics-plc-and-peak-bio-inc-is-complete 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/the-deep-dish-on-all-things-ophthalmology-at-aao-2024 2024-11-14 0.50 https://www.ophthalmologytimes.com/view/boehringer-ingelheim-joins-the-mary-tyler-moore-vision-initiative-to-combat-vision-loss-from-diabetes 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/european-commission-grants-marketing-authorization-to-biosimilar-from-sandoz-group 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/identifying-and-monitoring-ga-technologic-improvements-over-time 2024-11-14 0.50 https://www.ophthalmologytimes.com/view/wet-amd-therapeutics-technologies-raising-the-ceiling-for-functional-visual-outcomes 2024-11-14 0.50 https://www.ophthalmologytimes.com/view/advancements-in-ocular-drug-delivery 2024-11-13 0.50 https://www.ophthalmologytimes.com/view/a-field-guide-to-optic-disc-drusen 2024-11-13 0.50 https://www.ophthalmologytimes.com/view/new-data-on-pst-611-from-pulsesight-therapeutics-sas-shared-at-ever-congress-2024 2024-11-13 0.50 https://www.ophthalmologytimes.com/view/cencora-to-acquire-retina-consultants-of-america-for-up-to-5-1-billion- 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/fda-authorizes-marketing-of-valeda-light-delivery-system-for-treatment-of-patients-with-dry-amd 2024-11-12 0.50 https://www.ophthalmologytimes.com/view/fda-clears-investigational-new-drug-ind-application-for-hg202-by-huidagene-therapeutics 2024-11-12 0.50 https://www.ophthalmologytimes.com/view/noninvasive-choroidal-vessel-analysis-using-deep-learning-a-novel-approach-to-oct-angiography 2024-11-11 0.50 https://www.ophthalmologytimes.com/view/study-examines-the-use-of-ai-based-detection-of-diabetic-retinopathy-in-the-us 2024-11-11 0.50 https://www.ophthalmologytimes.com/view/ga-therapies-coming-down-the-pike 2024-11-07 0.50 https://www.ophthalmologytimes.com/view/patient-selection-for-ga-therapy 2024-11-07 0.50 https://www.ophthalmologytimes.com/view/e-therapeutics-shares-update-on-amd-candidate-etx-407 2024-11-08 0.50 https://www.ophthalmologytimes.com/view/rensselaer-polytechnic-institute-researchers-receive-grant-to-study-potential-dry-amd-treatment 2024-11-08 0.50 https://www.ophthalmologytimes.com/view/researchers-offer-insights-into-wet-amd-study-reveals-potential-to-enhance-anti-vegf-therapy-with-experimental-drug-to-preserve-vision 2024-11-08 0.50 https://www.ophthalmologytimes.com/view/osn-new-york-retina-2024-understanding-how-next-generation-anti-vegfs-perform-in-real-world-settings-compared-to-trials 2024-11-08 0.50 https://www.ophthalmologytimes.com/view/5-interviews-from-aao-2024-you-don-t-want-to-miss 2024-11-07 0.50 https://www.ophthalmologytimes.com/view/osn-new-york-retina-meeting-to-highlight-geographic-atrophy-and-diabetic-eye-conditions 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/researchers-focus-on-regenerative-treatments-for-age-related-conditions-including-amd 2024-11-06 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-recognizes-november-as-diabetes-related-eye-disease-awareness-month 2024-11-06 0.50 https://www.ophthalmologytimes.com/view/david-arkowitz-mba-joins-alkeus-pharmaceuticals-as-chief-financial-officer 2024-11-05 0.50 https://www.ophthalmologytimes.com/view/fda-grants-flq-101-fast-track-designation 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/acute-macular-neuroretinopathy-associated-with-covid-19-pandemic 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2024-preventing-and-managing-complications-following-vitreoretinal-surgery 2024-10-31 0.50 https://www.ophthalmologytimes.com/view/effect-of-caffeine-on-retinal-vessel-density 2024-11-01 0.50 https://www.ophthalmologytimes.com/view/aao-2024-management-of-the-vitreous-for-the-anterior-segment-surgeon 2024-10-31 0.50 https://www.ophthalmologytimes.com/view/aao-2024-aging-in-the-ophthalmology-profession 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2024-fundus-photography-oct-expediates-care-in-the-emergency-department 2024-11-21 0.50 https://www.ophthalmologytimes.com/view/changes-in-retinal-microvasculature-in-preclinical-alzheimer-s-disease 2024-10-30 0.50 https://www.ophthalmologytimes.com/view/gr8-eye-movement-data-spotlights-misconceptions-and-low-awareness-of-serious-retinal-diseases-among-caregivers-of-older-adults 2024-10-29 0.50 https://www.ophthalmologytimes.com/view/veterans-administration-ophthalmologist-invents-device-to-help-with-eye-drops 2024-10-29 0.50 https://www.ophthalmologytimes.com/view/aao-2024-ophthalmic-drop-wastage-due-to-artificial-expiration-date 2024-10-29 0.50 https://www.ophthalmologytimes.com/view/michelle-tarver-md-phd-named-permanent-director-of-the-fda-s-center-for-devices-and-radiological-health 2024-10-29 0.50 https://www.ophthalmologytimes.com/view/eyepoint-pharmaceuticals-reports-positive-16-week-interim-results-from-phase-2-verona-trial-of-duravyu-for-diabetic-macular-edema 2024-10-29 0.50 https://www.ophthalmologytimes.com/view/3d-printed-glasses-improve-sight-in-children-with-amblyopia-and-strabismus-in-remote-areas 2024-10-24 0.50 https://www.ophthalmologytimes.com/view/aao-2024-energy-drinks-and-central-retinal-vein-occlusions 2024-10-26 0.50 https://www.ophthalmologytimes.com/view/aao-2024-suprachoroidal-drug-delivery-in-the-real-world 2024-10-25 0.50 https://www.ophthalmologytimes.com/view/ophthalmic-drop-wastage-due-to-artificial-expiration-dates 2024-10-24 0.50 https://www.ophthalmologytimes.com/view/aao-2024-bonnie-an-henderson-md-explores-future-of-medical-education-in-kelman-lecture 2024-10-27 0.50 https://www.ophthalmologytimes.com/view/curcuma-based-nutritional-supplements-and-reduced-risk-of-amd 2024-10-25 0.50 https://www.ophthalmologytimes.com/view/visual-impairment-may-have-a-role-in-dementia 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/chemotherapy-for-high-risk-retinoblastoma-less-may-be-more 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2024-detail-outlined-for-artificial-intelligence-innovation-center-at-wilmer-eye-institute 2024-10-21 0.50 https://www.ophthalmologytimes.com/view/ocuphire-pharma-acquires-opus-genetics 2024-10-22 0.50 https://www.ophthalmologytimes.com/view/aao-2024-applying-large-language-models-in-revenue-cycle-management 2024-10-21 0.50 https://www.ophthalmologytimes.com/view/aao-2024-approaching-pregnant-women-across-the-ophthalmic-subspecialties 2024-10-18 0.50 https://www.ophthalmologytimes.com/view/aao-2024-new-drug-shows-promise-as-first-to-protect-vision-in-patients-with-dry-amd 2024-10-16 0.50 https://www.ophthalmologytimes.com/view/aao-2024-chloroprocaine-ophthalmic-gel-as-anesthesia-for-intravitreal-injections 2024-10-21 0.50 https://www.ophthalmologytimes.com/view/aao-2024-transient-vision-loss-with-alexander-fein-md 2024-10-20 0.50 https://www.ophthalmologytimes.com/view/aao-2024-incidence-and-prevalence-of-uveitis-and-associated-ocular-complications-in-the-us-trinetx-database 2024-10-20 0.50 https://www.ophthalmologytimes.com/view/aao-2024-deuterated-vitamin-a-preserves-vision-in-stargardt-disease 2024-10-16 0.50 https://www.ophthalmologytimes.com/view/aao-2024-the-use-of-teleretinal-screening-for-diabetic-retinopathy-with-christina-y-weng-md-mba 2024-10-16 0.50 https://www.ophthalmologytimes.com/view/aao-2024-defocus-curve-performance-of-trifocal-iols-and-near-activity-vision-questionnaire-outcomes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/phototherapeutic-keratectomy-assisted-customized-epi-on-corneal-crosslinking-a-different-approach-for-treating-keratoconus 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2024-epimacular-membranes-and-metamorphopsia 2024-10-24 0.50 https://www.ophthalmologytimes.com/view/aao-2024-the-treatment-for-stargardt-disease-in-adolescents 2024-10-18 0.50 https://www.ophthalmologytimes.com/view/aao-2024-retinal-structural-changes-in-children-with-ametropic-amblyopia 2024-10-14 0.50 https://www.ophthalmologytimes.com/view/aao-2024-risk-of-posterior-capsular-rupture-in-second-eye-of-patients-with-history-of-pcr 2024-10-16 0.50 https://www.ophthalmologytimes.com/view/risk-of-posterior-capsular-rupture-in-cataract-surgery-of-fellow-eyes 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-accelerates-timelines-for-sol-1-phase-3-trial-of-axpaxli-for-wet-amd 2024-10-17 0.50 https://www.ophthalmologytimes.com/view/aao-2024-long-term-low-dose-antiviral-treatment-benefits-patients-with-eye-disease-and-pain-from-shingles 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/eyenuk-and-aao-partner-to-bring-diabetic-retinopathy-screening-to-underserved-communities 2024-10-17 0.50 https://www.ophthalmologytimes.com/view/aao-2024-cell-phone-use-and-student-performance 2024-10-15 0.50 https://www.ophthalmologytimes.com/view/aao-launches-vr-education-program-in-collaboration-with-fundamentalvr-to-improve-worldwide-ophthalmic-care 2024-10-18 0.50 https://www.ophthalmologytimes.com/view/ai-powered-home-monitoring-device-improved-amd-care-money-savings 2024-10-18 0.50 https://www.ophthalmologytimes.com/view/aao-2024-livionex-reports-positive-end-of-phase-2-meeting-with-fda-on-the-development-of-c-kad-eye-drop-to-treat-early-to-moderate-cataracts 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/pmc-403-receives-unanimous-safety-approval-for-4mg-single-ascending-dose-cohort-in-phase-1-clinical-trial 2024-10-17 0.50 https://www.ophthalmologytimes.com/view/intravitreal-injections-for-amd-and-dme-may-complicate-cataract-surgery 2024-10-18 0.50 https://www.ophthalmologytimes.com/view/light-therapy-potential-treatment-for-dry-amd 2024-10-18 0.50 https://www.ophthalmologytimes.com/view/aao-2024-an-update-from-neurotech-on-mactel-treatment-candidate 2024-10-16 0.50 https://www.ophthalmologytimes.com/view/steven-yeh-md-shares-overview-of-recent-and-upcoming-presentations 2024-10-16 0.50 https://www.ophthalmologytimes.com/view/sterile-intraocular-inflammation-associated-with-faricimab 2024-10-17 0.50 https://www.ophthalmologytimes.com/view/case-2-management-of-progressive-geographic-atrophy-in-an-84-year-old-man 2024-10-17 0.50 https://www.ophthalmologytimes.com/view/case-1-management-and-treatment-considerations-for-an-89-year-old-woman-with-dry-amd-and-ga 2024-10-17 0.50 https://www.ophthalmologytimes.com/view/overview-of-ga-treatment-strategy-reflecting-on-roundtable-discussion 2024-10-17 0.50